Sort
10,766 grants matching “checkpoint inhibitor”
Mesothelin-targeted immunotoxins in Pancreatic Cancer
$799,976Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Regulation of the osmoprotective transcription factor NFAT5
$799,870Maurice Benjam Burg · National Heart, Lung, And Blood Institute · ZIA · FY2011 · HL
DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs
$799,704Yves Pommier · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer
$799,560Alexander B Sigalov · Signablok, Inc. · R44 · FY2019 · CA
Immune epigenetic biomarkers of survival in glioma epidemiology
$797,441John K. Wiencke · University Of California, San Francisco · R01 · FY2020 · CA
Mayo Clinic Breast Cancer SPORE
$797,371Matthew Philip Goetz · Mayo Clinic Rochester · P50 · FY2021 · CA
Epigenetic Therapy for Thoracic Malignancies
$796,884David Schrump · Division Of Clinical Sciences - Nci · ZIA · FY2022 · CA
Advancing treatment and understanding of immunotherapy in glioblastoma
$796,871Nicholas A Butowski · University Of California, San Francisco · U19 · FY2024 · CA
Exploring Siglec-glycan ligand interactions using chemoenzymatic approaches
$795,942Peng Wu · Scripps Research Institute, The · R01 · FY2022 · AI
Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers
$795,857Geoffrey I Shapiro · Dana-Farber Cancer Inst · R01 · FY2025 · CA
Mechanism and inhibition of SREBP-dependent cholesterol/lipid metabolism
$795,581Gerhard Wagner · Harvard Medical School · R01 · FY2016 · HL
Immunotherapeutic targeting of gangliosides in Ewing Sarcoma
$795,150Robbie G. Majzner · Dana-Farber Cancer Inst · U01 · FY2023 · CA
Clinical and Translational Investigations of Immune Suppression and Immune Modulation in Glioblastoma
$794,779Edjah Nduom · National Institute Of Neurological Disorders And Stroke · ZIA · FY2020 · NS
Pathway inhibitors in Lymphomas
$794,573Mark Roschewski · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Regulation of innate lymphocyte function
$794,415Eric O Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis
$794,337Justin M Balko · Vanderbilt University Medical Center · R01 · FY2024 · HL
Building the foundations of commensal vaccines
$794,261Michael Andrew Fischbach · Stanford University · R01 · FY2022 · AI
Gene Expression At The Beginning Of Mammalian Development
$793,077Melvin Depamphilis · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2012 · HD
Initiation Of DNA Replication In Mammalian Chromosomes
$793,077Melvin Depamphilis · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2012 · HD
Lymphoma Disease Discovery and Definition
$791,253Elaine Jaffe · Division Of Clinical Sciences - Nci · ZIA · FY2018 · CA
PROJECT 2: Development and Refinement of Predictive Models for Designing Immunotherapy Combination Treatments
$789,891Vesteinn Thorsson · Institute For Systems Biology · U54 · FY2022 · CA
Novel Approaches to Targeting Cancers Associated with VHL Mutations
$789,660Ramaprasad Srinivasan · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines
$787,127James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Immune response to MCMV infection in the salivary glands
$786,787Laurent Brossay · Brown University · R01 · FY2024 · AI
Immune response to MCMV infection in the salivary glands
$786,787Laurent Brossay · Brown University · R01 · FY2025 · AI